IGM BIOSCIENCES INC (IGMS) Fundamental Analysis & Valuation

NASDAQ:IGMS • US4495851085

Current stock price

1.27 USD
-0.03 (-2.31%)
At close:
1.28 USD
+0.01 (+0.79%)
After Hours:

This IGMS fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

2

1. IGMS Profitability Analysis

1.1 Basic Checks

  • IGMS had negative earnings in the past year.
  • IGMS had a negative operating cash flow in the past year.
  • In the past 5 years IGMS always reported negative net income.
  • IGMS had a negative operating cash flow in each of the past 5 years.
IGMS Yearly Net Income VS EBIT VS OCF VS FCFIGMS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M -200M -250M

1.2 Ratios

  • With a Return On Assets value of -49.53%, IGMS perfoms like the industry average, outperforming 51.00% of the companies in the same industry.
  • IGMS has a Return On Equity of -52.48%. This is in the better half of the industry: IGMS outperforms 64.85% of its industry peers.
  • IGMS's Return On Invested Capital of 7.99% is amongst the best of the industry. IGMS outperforms 93.26% of its industry peers.
Industry RankSector Rank
ROA -49.53%
ROE -52.48%
ROIC 7.99%
ROA(3y)-58.3%
ROA(5y)-50.04%
ROE(3y)-202.16%
ROE(5y)-139.04%
ROIC(3y)N/A
ROIC(5y)N/A
IGMS Yearly ROA, ROE, ROICIGMS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 0 -5K -10K -15K

1.3 Margins

  • IGMS has a Operating Margin of 7.04%. This is amongst the best in the industry. IGMS outperforms 91.62% of its industry peers.
  • The Profit Margin and Gross Margin are not available for IGMS so they could not be analyzed.
Industry RankSector Rank
OM 7.04%
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
IGMS Yearly Profit, Operating, Gross MarginsIGMS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 -5K -10K -15K -20K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. IGMS Health Analysis

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), IGMS is destroying value.
  • IGMS has more shares outstanding than it did 1 year ago.
  • The number of shares outstanding for IGMS has been increased compared to 5 years ago.
  • IGMS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
IGMS Yearly Shares OutstandingIGMS Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
IGMS Yearly Total Debt VS Total AssetsIGMS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

2.2 Solvency

  • IGMS has an Altman-Z score of -2.33. This is a bad value and indicates that IGMS is not financially healthy and even has some risk of bankruptcy.
  • IGMS has a Altman-Z score of -2.33. This is comparable to the rest of the industry: IGMS outperforms 50.09% of its industry peers.
  • IGMS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -2.33
ROIC/WACC0.82
WACC9.76%
IGMS Yearly LT Debt VS Equity VS FCFIGMS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M -200M 300M

2.3 Liquidity

  • IGMS has a Current Ratio of 17.66. This indicates that IGMS is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Current ratio, with a value of 17.66, IGMS belongs to the top of the industry, outperforming 92.71% of the companies in the same industry.
  • A Quick Ratio of 17.66 indicates that IGMS has no problem at all paying its short term obligations.
  • IGMS has a Quick ratio of 17.66. This is amongst the best in the industry. IGMS outperforms 92.71% of its industry peers.
Industry RankSector Rank
Current Ratio 17.66
Quick Ratio 17.66
IGMS Yearly Current Assets VS Current LiabilitesIGMS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. IGMS Growth Analysis

3.1 Past

  • IGMS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 85.01%, which is quite impressive.
  • IGMS shows a strong growth in Revenue. In the last year, the Revenue has grown by 4881.11%.
EPS 1Y (TTM)85.01%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%300%
Revenue 1Y (TTM)4881.11%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%11353.19%

3.2 Future

  • The Earnings Per Share is expected to grow by 11.78% on average over the next years. This is quite good.
  • IGMS is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 18.08% yearly.
EPS Next Y59.87%
EPS Next 2Y27.79%
EPS Next 3Y19.3%
EPS Next 5Y11.78%
Revenue Next Year249.45%
Revenue Next 2Y126.25%
Revenue Next 3Y73.98%
Revenue Next 5Y18.08%

3.3 Evolution

IGMS Yearly Revenue VS EstimatesIGMS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 5M 10M
IGMS Yearly EPS VS EstimatesIGMS Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 -1 -2 -3 -4 -5

More info and screens

Find the best growth stocksShow best growing peers

0

4. IGMS Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for IGMS. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for IGMS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
IGMS Price Earnings VS Forward Price EarningsIGMS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA -5.77
IGMS Per share dataIGMS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 -2

4.3 Compensation for Growth

  • IGMS's earnings are expected to grow with 19.30% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y27.79%
EPS Next 3Y19.3%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. IGMS Dividend Analysis

5.1 Amount

  • IGMS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

IGMS Fundamentals: All Metrics, Ratios and Statistics

IGM BIOSCIENCES INC

NASDAQ:IGMS (8/13/2025, 8:15:46 PM)

After market: 1.28 +0.01 (+0.79%)

1.27

-0.03 (-2.31%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)07-31
Earnings (Next)11-06
Inst Owners53.06%
Inst Owner ChangeN/A
Ins Owners2.48%
Ins Owner Change0%
Market Cap76.57M
Revenue(TTM)145.05M
Net Income(TTM)-53.00M
Analysts48.89
Price Target1.27 (0%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)297.19%
Min EPS beat(2)-21.95%
Max EPS beat(2)616.34%
EPS beat(4)2
Avg EPS beat(4)147.4%
Min EPS beat(4)-23.77%
Max EPS beat(4)616.34%
EPS beat(8)5
Avg EPS beat(8)-167.29%
EPS beat(12)9
Avg EPS beat(12)-109.67%
EPS beat(16)12
Avg EPS beat(16)-83.61%
Revenue beat(2)1
Avg Revenue beat(2)2105.97%
Min Revenue beat(2)-84.23%
Max Revenue beat(2)4296.17%
Revenue beat(4)3
Avg Revenue beat(4)1075.96%
Min Revenue beat(4)-84.23%
Max Revenue beat(4)4296.17%
Revenue beat(8)3
Avg Revenue beat(8)515.32%
Revenue beat(12)5
Avg Revenue beat(12)338.08%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-33.33%
EPS NQ rev (1m)37.73%
EPS NQ rev (3m)-16%
EPS NY rev (1m)0%
EPS NY rev (3m)-20.2%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-4.27%
Revenue NY rev (1m)0%
Revenue NY rev (3m)57.03%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.53
P/FCF N/A
P/OCF N/A
P/B 0.76
P/tB 0.76
EV/EBITDA -5.77
EPS(TTM)-0.55
EYN/A
EPS(NY)-1.19
Fwd EYN/A
FCF(TTM)-2.62
FCFYN/A
OCF(TTM)-2.59
OCFYN/A
SpS2.41
BVpS1.67
TBVpS1.67
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -49.53%
ROE -52.48%
ROCE 10.11%
ROIC 7.99%
ROICexc N/A
ROICexgc N/A
OM 7.04%
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-58.3%
ROA(5y)-50.04%
ROE(3y)-202.16%
ROE(5y)-139.04%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover1.36
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA 0
Cap/Depr 29.58%
Cap/Sales 1.5%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 17.66
Quick Ratio 17.66
Altman-Z -2.33
F-Score5
WACC9.76%
ROIC/WACC0.82
Cap/Depr(3y)125.69%
Cap/Depr(5y)474.33%
Cap/Sales(3y)578.65%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)85.01%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%300%
EPS Next Y59.87%
EPS Next 2Y27.79%
EPS Next 3Y19.3%
EPS Next 5Y11.78%
Revenue 1Y (TTM)4881.11%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%11353.19%
Revenue Next Year249.45%
Revenue Next 2Y126.25%
Revenue Next 3Y73.98%
Revenue Next 5Y18.08%
EBIT growth 1Y104.31%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year61.17%
EBIT Next 3Y22.7%
EBIT Next 5YN/A
FCF growth 1Y19.14%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y14.46%
OCF growth 3YN/A
OCF growth 5YN/A

IGM BIOSCIENCES INC / IGMS Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for IGM BIOSCIENCES INC?

ChartMill assigns a fundamental rating of 3 / 10 to IGMS.


What is the valuation status of IGM BIOSCIENCES INC (IGMS) stock?

ChartMill assigns a valuation rating of 0 / 10 to IGM BIOSCIENCES INC (IGMS). This can be considered as Overvalued.


Can you provide the profitability details for IGM BIOSCIENCES INC?

IGM BIOSCIENCES INC (IGMS) has a profitability rating of 2 / 10.


What is the earnings growth outlook for IGM BIOSCIENCES INC?

The Earnings per Share (EPS) of IGM BIOSCIENCES INC (IGMS) is expected to grow by 59.87% in the next year.